Analysts at Dawson James Securities recently initiated coverage on Dyadic with a Buy rating citing the effectiveness of the biotechnology company’s C1 gene expression platform.
Dyadic 'advancing the ball down the field' with Wall St, and its C1 gene expression platform
Quick facts: Dyadic International Inc
Price: 5.99 USD
Market Cap: $164.54 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE